ArticlePLoS genetics2026
mFABIO: An integrative multi-tissue TWAS fine-mapping approach to prioritize potentially causal genes and tissues underlying binary traits.
Article in PLoS genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in transcriptome-wide association study (TWAS) fine-mapping have enabled the joint modeling of multiple genes to improve causal gene prioritization. However, existing methods have been developed primarily for quantitative traits and most of them rely on gene expression data from a single tissue. Here, we present mFABIO, a multi-tissue TWAS fine-mapping method specifically designed for binary traits. mFABIO employs a probit model to directly link genetically regulated expression (GReX) of genes within a locus across multiple tissues to a binary outcome, while accounting for correlations in GReX across genes and tissues. As a result, mFABIO offers substantial power gains for binary traits, while maintaining robust control of false discovery rates (FDR). We evaluated mFABIO through extensive simulations and applied it to an in-depth analysis of six binary disease traits (asthma, breast cancer, gout, hypertension, prostate cancer, and rheumatoid arthritis) in the UK Biobank, using expression data spanning 38 Genotype-Tissue Expression (GTEx) tissues. mFABIO identified an average of 42 likely causal genes and 65 tissue-gene pairs per disease (FDR < 0.05). Notably, 60.9% of the genes and 77.2% of the gene-tissue pairs were supported by existing TWAS or GWAS evidence. This represented at least a 14.9% increase in evidence-supported genes and a 14.8% increase in evidence-supported gene-tissue pairs, compared to existing approaches. Additionally, mFABIO was also able to narrow down the list of potentially causal candidates by at least 51.3% for genes, and 50.8% for gene-tissue pairs, compared to single-tissue approaches. Leveraging its improved power, mFABIO successfully prioritized multiple potentially causal gene-tissue pairs associated with these diseases, with biological support. Notable examples include D2HGDH in lung tissue for asthma, CYBRD1 in breast mammary tissue for breast cancer, and CCR6 in spleen tissue for rheumatoid arthritis. Overall, mFABIO serves as an effective tool for multi-tissue TWAS fine-mapping of binary traits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.